Q1 2023 Non-GAAP Operating Income

UZEDY™ (risperidone) Now Approved 2 RAPID ABSORPTION Achieves therapeutic levels in plasma within 6 to 24 hours of administration 1,2 STREAMLINED INITIATION No loading dose or oral supplementation is required² FLEXIBLE 1- AND 2-MONTH DOSING INTERVALS Two dosing intervals and 8 dosing options² SUBCUTANEOUS INJECTION Administered as a single-dose, prefilled syringe with a short, 5/8-inch needle² DEMONSTRATED EFFICACY and KNOWN SAFETY PROFILE Significant reductions in the risk of relapse vs placebo² Safety profile expected to be similar to that of corresponding oral risperidone doses* UZEDY. (risperidone) extended-release injectable suspension ~$4B LAI 2022 Market size 1 month dosing UZEDY. (risperidone) FOR SUBCUTANEOUS USE ONLY 2 month dosing UZEDY (risperidone) FOR SUBCUTANEOUS USE ONLY For administration by a leathcare professional Rx Only NDC 51750-900-10 One side-dose predige 250mg/0.7mL at every two For administration by a healthcare professional NDC 51759-630-10 Rx Only One single-dose prefed syringe 125mg/0.35 mL astered every are th Stor in refrigerator at the original controlectron to 730 minutes prior to a ints packaging at room temperature at 20°C to 25°C he administration 1625 1997 maybe od kupa el storage with 50 day ed to friga 0 de uniese may Be the cartoni edad OPEN HERE teva ct from ligh teva | 11 | References: 1. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 2. UZEDYTM (risperidone) extended-release injectable suspension Current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. * The most common adverse reactions with risperidone (≥5% and greater than placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. The most common injection site reactions with UZEDY (25% and greater than placebo) were pruritus and nodule. teva

View entire presentation